Aprea Therapeutics, Inc. 8-K

What Happened

• On May 13, 2026, Aprea Therapeutics, Inc. announced its financial results and operational update for the quarter ended March 31, 2026 via a press release (furnished as Exhibit 99.1 to the Form 8-K). The company also updated its corporate presentation slide deck (filed as Exhibit 99.2). The report was signed by President and CEO Oren Gilad, Ph.D.

Key Details

• Filing date: May 13, 2026 (Form 8-K).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Press release with quarterly results and operations update: Exhibit 99.1.
• Updated corporate presentation (May 2026): Exhibit 99.2.

Why It Matters

• This 8-K gives investors the company’s latest quarterly results and an updated investor deck — primary sources for assessing recent revenue, expenses, cash position, and program progress. Review the attached press release and slide deck for the specific financial figures and operational details investors use to evaluate near-term performance and strategy.